Market Access Views from Asembia: EVERSANA's take on outsourcing, AI, and ... Following Asembia 2026, pharmaphorum spoke with Krista Pinto, a leading commercialisation expert at EVERSANA.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
